Jennifer Eng‐Wong

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Josep Tabernero, Paulo M. Hoff, Lin Shen et al. · The Lancet Oncology · 2018 · 468 citations

Surgical Oncology, Her2-positive Metastatic Gastric, Placebo-controlled Phase 3 +8

Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

Minetta C. Liu, Peter G. Shields, Robert Warren et al. · Journal of Clinical Oncology · 2009 · 312 citations · Full text

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Stephen J. Luen, Roberto Salgado, Stephen B. Fox et al. · The Lancet Oncology · 2016 · 284 citations · Full text

Breast Oncology, Medicine, Immunology +8

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

Andreas Schneeweiß, Stephen Chia, Tamas Hickish et al. · European Journal of Cancer · 2017 · 270 citations

Breast Oncology, Oncology, Safety Study +7

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Sandra M. Swain, Michael S. Ewer, Giuseppe Viale et al. · Annals of Oncology · 2017 · 237 citations · Full text